Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Lactobacillus Reuteri for Obesity-Induced Skin Barrier Impairment
NCT07512050Not yet recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Live Biotherapeutic Products
01
Overview
Randomised, double-blind trial of lactobacillus reuteri in skin barrier impairment (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Transepidermal Water Loss at 1 month. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
lactobacillus reuteri
03
Conditions
skin barrier impairment
Beyond the preview
Go deeper on NCT07512050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512050.